View ValuationAlamar Biosciences 향후 성장Future 기준 점검 2/6Alamar Biosciences (는) 각각 연간 24.2% 및 30% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 77% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -13.4% 로 예상됩니다.핵심 정보24.2%이익 성장률76.99%EPS 성장률Life Sciences 이익 성장16.9%매출 성장률30.0%향후 자기자본이익률-13.43%애널리스트 커버리지Low마지막 업데이트08 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates속보 • Jun 04Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.공시 • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.공시 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha공시 • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering이익 및 매출 성장 예측NasdaqGS:ALMR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028221-35-22-26412/31/2027162-57-48-29512/31/2026113-73-66-5353/31/202687-43-67-61N/A12/31/202574-30-60-54N/A12/31/202425-46-59-55N/A애널리스트 향후 성장 전망수입 대 저축률: ALMR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ALMR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ALMR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ALMR 의 수익(연간 30%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: ALMR 의 수익(연간 30%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ALMR는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 17:45종가2026/07/06 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Alamar Biosciences, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael RyskinBofA Global ResearchCasey WoodringJ.P. MorganPuneet SoudaLeerink Partners LLC2명의 분석가 더 보기
속보 • Jun 04Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.
공시 • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
공시 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha
공시 • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering